Back to Journals » The Application of Clinical Genetics » Volume 3

Management of the asymptomatic BRCA mutation carrier

Authors Teller P, Kramer R

Published 24 November 2010 Volume 2010:3 Pages 121—131

DOI https://doi.org/10.2147/TACG.S8882

Review by Single anonymous peer review

Peer reviewer comments 1


Paige Teller1, Rita K Kramer2
1Surgical Oncology, 2Medical Oncology, Medical University of South Carolina, Charleston, SC, USA

Abstract: Current management of an asymptomatic BRCA mutation carrier includes early initiation and intensive cancer screening in combination with risk reduction strategies. The primary objectives of these interventions are earlier detection and cancer prevention to increase quality of life and prolonged survival. Existing recommendations are often based on the consensus of experts as there are few, supportive, randomized control trials. Management strategies for unaffected patients with BRCA mutations are continually redefined and customized as more evidence-based knowledge is acquired with regard to current intervention efficacy, mutation-related histology, and new treatment modalities. This review provides an outline of current, supported management principles, and interventions in the care of the asymptomatic BRCA mutation carrier. Topics covered include surveillance modalities and risk reduction achieved through behavioral modification, chemoprevention, and prophylactic surgery.

Keywords: high risk, screening, risk reduction, hereditary breast cancer syndrome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]